Kornimate/medical-research-clean huggingface dataset:
effectiveness of web-based education on premenstrual syndrome and quality of life

Conditions: Premenstrual Syndrome; Quality of Life

Summary: digital solutions are becoming increasingly prevalent, addressing health concerns through innovative means has become imperative. among these concerns, premenstrual syndrome (pms) stands out as a significant challenge that affecting the physical and emotional well-being of women of reproductive age. despite previous studies demonstrating the effectiveness of health education for pms, there remains a gap in providing accessible and evidence-based interventions. the present study aims to fill this gap leveraging technology to deliver targeted information and support to women. for this reason, the purpose of this randomized controlled trial is to evaluate the effectiveness of a web-based health education in university students with pms. the main questions it aims to answer are: * does web-based education lower the premenstrual symptoms in university students with pms? * does web-based education improve the quality of life in university students with pms? researchers compared web-based education to a control (no special intervention) to see if intervention works to management pms. intervention group participants received web-based education with weekly updates about pms (definition, symptoms, treatment etc.) and management strategies for 4 weeks.

the study was planned as a parallel, single-blind, randomized, controlled experimental study with a pretest-posttest design. the sample group of the research was the nursing department of a faculty of health sciences in pamukkale university. eligibility was determined by the premenstrual syndrome scale and personal information form. the sample size was calculated in the ps power and sample size calculations 3.1.6 program by using data from a previous study with a large effect size (α =0.05, d=0.86). accordingly, it was found that at least 32 participants should be taken for each group to sampling for 80% power. to avoid possible data loss, all participants (n=74) determined to be eligible were included in the study. a simple randomization method was used in this study. outcomes were measured at baseline, 4 weeks, and 12 weeks after the intervention began. data were collected using the premenstrual syndrome scale, premenstrual symptoms impact scale, system usability scale, and personal information form.

Eligibility criteria:
inclusion criteria: * pms (pmss score of 132+) * normal menstrual cycle (21-35 days) * no oral contraceptives * no psychiatric problems or treatment * active internet use * over 18 * volunteering to participate in research exclusion criteria: * internet access problems * website login issues * unanswered survey questions

Keywords: premenstrual syndrome web-based nurse-led health education quality of life
investigative headgear with nasal pillows continuous positive airway pressure (cpap) mask

Conditions: Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the at-home usability, performance, user acceptance and reliability of the headgear with a cpap mask for a duration of 6 months.

20 participants will be recruited for the trial, consisting of male and female participants diagnosed with osa and receiving cpap or bi-level positive airway pressure (pap) for the treatment of their obstructive sleep apnea (osa). these include current cpap mask users.

Eligibility criteria:
inclusion criteria: * ahi≥5 from the diagnostic night * ≥18 years of age * prescribed cpap or bi-level therapy for osa * existing f\&p pilairo q, eson, simplus mask users exclusion criteria: * inability to give informed consent * patient intolerant to cpap * anatomical or physiological conditions making cpap therapy inappropriate * history of respiratory disease or carbon dioxide (co2) retention * pregnant or think they may be pregnant * investigated by land transport safety authority
effect of integrated neuromuscular inhibition technique in females with menstrual low back pain

Conditions: Dysmenorrhea

Summary: dysmenorrhea is a common problem in women of reproductive age. primary dysmenorrhea is defined as recurrent, cramping pain occurring with menses in the absence of identifiable pelvic pathology .

primary dysmenorrhea is characterized by a crampy supra-pubic pain that begins somewhere between several hours before and a few hours after the onset of the menstrual bleeding. symptoms peak with maximum blood flow and usually last less than one day, but the pain may persist up to 2 to 3 days. symptoms are more or less reproducible from one menstrual period to the other. the pain is characteristically colicky and located in the midline of the lower abdomen and may extend to lower quadrants, the lumbar area, and the thighs. menstrual low back pain (lbp) is one of the common complaints among women. previous studies have indicated that more than 40% to 50% of the population experience lbp during the menstrual phase (days 1-6) of the menstrual cycle .

Eligibility criteria:
inclusion criteria: 1. thirty adolescent females suffering from menstrual low back pain. 2. their age will be ranged from 17 to 24 years. 3. their body mass index will be ranged from 20 to 25 kg/m2. exclusion criteria: 1. personal and individual differences between the subjects. 2. psychological and physical status of subjects which may affect the treatment and evaluation stage. 3. environmental factors which may affect the subject's response
analysis of a new mask for positive airway pressure (pap) device users

Conditions: Obstructive Sleep Apnea

Summary: background and aims continuous positive airway pressure (cpap) is an effective therapy to treat sleep apnea. sleep apnea is a condition where the airways collapse when the patient is asleep. cpap treats sleep apnea by delivering an air pressure to the airways, splinting the airways open. cpap is a device that sits besides the bed and is applied to the patient using a face mask. the development of new cpap masks is an on-going focus at resmed ltd in a bid to improve comfort and user compliance. resmed are developing a new mask and investigations are required to evaluate mask performance over time. resmed ltd design and manufacturer cpap masks. the revision and development of masks is an on-going focus of the company in a bid to improve usability and patient compliance while maintaining optimum treatment. resmed is developing a new mask. investigations are therefore required to determine how much matter is built-up on the mask over time and to evaluate mask performance (including comfort and seal) and efficacy. aims the aims of the study are: 1. to measure and compare the change in the abundance of microbes on the new mask over a period of 8 weeks 2. to measure and compare the change in comfort, seal, stability, efficacy, leak and user compliance of this new mask over a period of 8 weeks 3. to measure and compare the change in comfort, seal, stability, efficacy, leak and user compliance of this new mask versus an available mask it is hypothesised that: 1. the new mask acquires microbes from the user but there is no difference in the abundance of microorganisms between 2 and 8 weeks. 2. the new mask maintains the same degree of comfort, seal, stability, efficacy, leak and compliance between 2 and 8 weeks. 3. compared to the existing mask, the new mask provides a higher degree of comfort, seal and stability and improves user compliance. the new mask also maintains efficacy, and maintains or reduces leak compared to the current masks.


Eligibility criteria:
inclusion criteria: * at least 18 yrs old * diagnosed with obstructive sleep apnoea * been using cpap therapy for at least 6 months exclusion criteria: * has a lung disease/condition * using bilevel therapy * is unable to participate for the duration of the study

Keywords: cpap mask microorganisms
safety and efficacy of oral mega pulse methylprednisolone in severe therapy resistant alopecia areata

Conditions: Alopecia Totalis; Alopecia Universalis; Ophiasic Alopecia

Summary: systemic pulse glucocorticoids have been shown to be effective in widespread alopecia areata but not the totalis, universalis or ophiasic type. whether the failure is due to inadequate dosing, inadequate frequency or other factors is a matter of debate. the investigators decided to conduct this study using the oral pulse steroid, however with higher doses and more frequent pulses to patients with severe forms of alopecia areata.

this will be a single-center, prospective, randomized study conducted in king khalid university hospital. patients diagnosed with either alopecia universalis, alopecia totalis or ophiasic alopecia will be included in the study. patients with contraindications such as diabetes mellitus, peptic ulcer, hypertension, infection, psychosis, heart or kidney disease, endocrine disorders (apart from a subclinical hypothyroidism and autoimmune thyroiditis) will be excluded. children less than 5 years of age and those who received systemic or topical treatment within the last 4 weeks before enrollment will be also excluded. those of child bearing potential had to have a negative urine pregnancy test result at baseline visit and should practice a reliable method of contraception throughout the study. 42 eligible patients will be randomly assigned to one of 3 treatment groups. enrolled patients must provide written informed consent. institutional review board approval will be obtained.

Eligibility criteria:
inclusion criteria: * alopecia universalis * alopecia totalis * ophiasic alopecia exclusion criteria: * diabetes mellitus * peptic ulcer * hypertension * infection * psychosis * heart disease * kidney disease * endocrine disorders (apart from a subclinical hypothyroidism and autoimmune thyroiditis) * received systemic or topical treatment within the last 4 weeks before enrollment * pregnancy

Keywords: alopecia areata alopecia totalis alopecia universalis ophiasic alopecia oral pulse steroid methylprednisolone
relationship between magnesium depletion score and extraction socket healing

Conditions: Wound Healing; Magnesium Level; Wisdom Tooth Removal

Summary: the surgical extraction of an impacted tooth is one of the most common procedures in oral surgery. following extraction, the tissue undergoes repair and regeneration through a process known as socket healing (sh). sh is a complex and highly regulated biological process. several local, surgical, and systemic factors can influence sh. this study aimed to evaluate the impact of the magnesium depletion score (mds) on the socket healing following tooth extraction.

the surgical extraction of impacted teeth is one of the most commonly performed procedures in the field of oral surgery. according to the american dental association (ada), surgical extraction involves "the removal of a tooth that has either erupted or not into the mouth, which includes the removal of a mucoperiosteal flap and the trimming of a portion of the tooth and/or bone." complications related to post-extraction wound healing-such as pain, swelling, bleeding, and infection-can pose significant challenges for both patients and surgeons. optimal healing depends not only on the tissue itself but also on various local, surgical, and systemic factors, including but not limited to the patient's stress levels, oral hygiene, age, sex, overall health status, and nutrition, many of which may be beyond intervention or control. consequently, there is growing interest in treatments that can enhance wound healing. recent studies indicate that magnesium consumption may have a beneficial effect on the healing process.

Eligibility criteria:
inclusion criteria: * systemically healthy adult participants who were scheduled to undergo surgical extraction of lower impacted third molars. exclusion criteria: * refusal to consent * presence of chronic diseases * use of medications that affect wound healing (steroids, bisphosphonate, or immunosuppressives) * prior radiotherapy in the head and neck area * pregnancy * inability to self-evaluate, and inability to communicate verbally or in writing.

Keywords: blood magnesium level oral surgery wound healing
cost-effectiveness study comparing chlorhexidine bathing with active surveillance cultures to prevent methicillin-resistant staphylococcus aureus & other hospital infections

Conditions: Staphylococcal Infections

Summary: this pilot study in our medical intensive care unit will evaluate the clinical and cost-effectiveness of an active surveillance program for methicillin-resistant staphylococcus aureus (mrsa), compared to routine daily bathing with chlorhexidine gluconate (chg)-impregnated cloths. outcomes include rate of mrsa acquisition, and of other hospital-acquired infections (e.g., catheter-associated bloodstream infections).


Eligibility criteria:
inclusion criteria: * all patients admitted to the medical intensive care unit (icu) are eligible for inclusion exclusion criteria: * patient refusal * contraindication to nasal swabbing (arm 1) * allergy/sensitivity to chlorhexidine gluconate (chg) (arm 2)

Keywords: methicillin resistance infection control staphylococcus aureus cross infection epidemiology chlorhexidine
efficacy and safety study to evaluate mt-6548 in hemodialysis subjects not receiving esas with anemia associated with chronic kidney disease in japan

Conditions: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Summary: for hemodialysis subjects not receiving esas with anemia associated with chronic kidney disease, evaluate hb correction and maintenance effect and safety of mt-6548.


Eligibility criteria:
inclusion criteria: * diagnosis of ckd * receiving hemodialysis or hemodiafiltration 3 times a week for more than 12 weeks prior to the screening period, excluding receiving home dialysis or combination of peritoneal dialysis. * not being treated with esas or if being treated with esas, leave defined interval between last esas administration and the first day of the screening period * mean of the two screening hb levels closest in time to the baseline visit is ≥8.0 g/dl and \<10.0 g/dl * fluctuation between the two hb levels closest in time to the baseline visit during the screening period less than 1.5 g/dl * serum ferritin ≥ 100 ng/ml, or tsat ≥20% during the screening period * folate and vitamin b12 ≥ lower limit of normal during the screening period exclusion criteria: * anemia due to a main cause other than ckd: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia * active bleeding or recent blood loss within 8 weeks prior to the screening period * rbc transfusion within 8 weeks prior to the screening period * received testosterone enanthate or mepitiostane within 8 weeks prior to the screening period * ast, alt, or total bilirubin \>2.5 x upper limit of normal during the screening period * uncontrolled hypertension (diastolic blood pressure \>110 mm hg or systolic blood pressure \>180 mm hg) at the first day of the screening period and day 1 * ophthalmic examinations during the screening period correspond to either of the following criteria; * no available fundal findings * findings indicating the presence of active fundal disease * severe heart failure (new york heart association class iv) * cerebrovascular disorder or acute coronary syndrome (hospitalization due to unstable angina or myocardial infarction), requiring hospitalization due to urgent percutaneous intervention for coronary or heart failure within 12 weeks prior to the screening period * current or history of malignancy. history of malignancy with no recurrence for the recent 5 years is not an exclusion criterion * new onset or recurrent event of deep vein thrombosis or pulmonary embolism within 12 weeks prior to the screening period * current or history of hemosiderosis or hemochromatosis * history of prior organ transplantation or scheduled organ transplant, or prior transplantation of hematopoietic stem cell or bone marrow * males and females of childbearing potential who are unwilling to use an acceptable method of contraception during the designated period (males: during the study and 90 days after the last dose, females: during study and 30 days after the last dose) * females who are pregnant or breast feeding, or are predicted to be pregnant
yellow 560 microscope for intraoperative visualization of fluorescein stained intracranial lesions

Conditions: Cerebrovascular Disorders; Intracranial Neoplasms

Summary: this study focuses on implementing yellow 560 for the direct intraoperative visualization of fluorescein sodium stained intracranial lesions to facilitate extend of surgery, develop better treatment protocols, and improve the prognosis of a wide array of neurosurgical diseases. more specifically, for the patients who are undergoing surgical intervention for the treatment of their brain aneurysm, tumor, arteriovenous malformation or fistula, the investigators will inject the dye intraoperatively to assess for residual aneurysm, tumor or in general residual lesion which must be corrected.

the research design is a prospective clinical study. all patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. at the time of the anesthesia induction, with the patient under general anesthesia, fluorescein sodium 10% (100mg/1ml) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). surgery will continue with the aid of the yellow 560 microscope with a minimum delay of 10 minutes after injection to reduce the amount of leakage of fluorescein sodium into the surrounding tissue. conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. the surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the fluorescein angiography demonstrates. for vascular lesions, fluorescein sodium 10% (100mg/1ml) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. no patient's care will be affected by the results of the fluorescein angiography. no other additional neurosurgical instruments will be used. patients will be treated post-operatively with conventional adjunctive therapies and imaging as deemed necessary by the attending neurosurgeon for the evaluation of extent of surgery. follow-up data (including post-operative images assessing outcomes and complications) will be collected on all patients on standard post-operative visits. intra-operative films or recordings and all patient data may be saved and used according to hipaa allowances.

Eligibility criteria:
inclusion criteria: * adult patients (age ≥ 18) * diagnosed by preoperative imaging modalities to have a brain tumor (including metastatic brain tumors) or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention. * the patient is determined by a board certified neurosurgeon to have a tumor or vascular lesion that would take up fluorescein * patient or legally authorized representative provides written informed consent to enroll in this study
comparison of the effects of vapocoolant spray and emla cream on pain during needle electromyography

Conditions: Electrodiagnosis

Summary: the purpose of this study is to compare the effects of vapocoolant spray and topical lidocaine 2.5% + prilocaine 2.5% cream (emla) on reducing pain during needle electromyography.

the study was conducted on patients with patients that underwent needle emgs in the lower extremity between july and august 2011 at the university hospital. the patients were divided into a total of three groups by random assignment: a control group that did not receive pretreatment, a group that received ethyl chloride vapocoolant spray and a group that received topical anesthetic cream (emla cream®).the patients with spray group, they were sprayed with ethyl chloride vapocoolant spray for 5 seconds from a distance of 30 cm just before the needle emg, and patients with emla cream, they received an application of topical anesthetic cream on the needle electrode insertion site 60 minutes before the needle emg. the 37-mm monopolar needle electrode was vertically inserted into the medial head of the gastrocnemius muscle in all patients. to assess the degree of pain for each group, patients were asked to indicate their level of pain on a 100 mm vas (0, no pain; 100, worst intolerable pain) after the needle emg in the gastrocnemius muscle. in both experimental groups, a 5-point likert scale was used to evaluate patient satisfaction with the pain reduction method used and their willingness to use the same analgesic method in another emg.

Eligibility criteria:
inclusion criteria: * patients who had a normal schedule of needle emgs in the lower extremity. exclusion criteria: 1. those who refused to participate in the experiment 2. those who were unable to understand a vas and likert scale 3. those with a history of allergic reaction to vapocoolant spray or lidocaine 4. those with a history of cold intolerance (raynaud's syndrome, etc.) 5. those who took oral pain medications or used topical anesthetics within 24 hours of the experiment 6. those who exhibited abnormal lower extremity sensation during the physical examination or who showed pain on gastrocnemius
study of a special vessel subtype in bone samples from patients with osteoporotic and nonosteoporotic fracture

Conditions: Femoral Neck Fractures

Summary: rationale: collecting and storing bone samples from patients with osteoporotic and nonosteoporotic fracture to study a special vessel subtype in the laboratory may help surgeon learn more about the relationship between bone mineral density (bmd) and a special vessel subtype (type h vessel). purpose: this research study is looking at changes of a special vessel subtype in bone samples from patients with osteoporotic and nonosteoporotic fracture.

objectives: 1. establish type h vessel in bone specimen in patients with hip fracture. 2. explore the correlation of bmd and type h vessel. outline: 1. collect human bone specimens from patients with osteoporotic and nonosteoporotic fracture. 2. provide a repository for storage of tissue and make these specimens available for approved projects by laboratory-based investigators. 3. observe the type h vessel in bone slice by immunofluorescence staining. 4. collect clinical data on these patients including bone mineral density. 5. investigate the relationship between bmd and type h vessel.

Eligibility criteria:
inclusion criteria: 1. ages eligible for study: 65-75 years 2. genders eligible for study: woman 3. accepts healthy volunteers: no 4. study population: female patients with hip fracture. - exclusion criteria: 1. malignancy or benign ovarian cysts 2. known chronic or systemic diseases 3. hormone therapy in the previous 3 months 4. bone metabolism and drug therapy